• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重的 COVID-19 是由 SARS-CoV-2 引发的 T 细胞免疫失调疾病。

Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.

机构信息

Department of Clinical Immunology, Auckland Hospital, Grafton Auckland, New Zealand.

Department of Virology and Immunology, Auckland Hospital, Grafton Auckland, New Zealand.

出版信息

Expert Rev Clin Immunol. 2022 Jun;18(6):557-565. doi: 10.1080/1744666X.2022.2074403. Epub 2022 May 26.

DOI:10.1080/1744666X.2022.2074403
PMID:35510369
Abstract

INTRODUCTION

COVID-19 has had a calamitous impact on the global community. Apart from at least 6 M deaths, hundreds of millions have been infected and a much greater number have been plunged into poverty. Vaccines have been effective but financial and logistical challenges have hampered their rapid global deployment. Vaccine disparities have allowed the emergence of new SARS-CoV-2 variants including delta and omicron, perpetuating the pandemic.

AREAS COVERED

The immunological response to SARS-CoV-2 is now better understood. Many of the clinical manifestations of severe disease are a consequence of immune dysregulation triggered by the virus. This may explain the lack of efficacy of antiviral treatments, such as convalescent plasma infusions, given later in the disease.

EXPERT OPINION

T cells play a crucial role in both the outcome of COVID-19 as well as the protective response to vaccines. Vaccines do not prevent infection but reduce the risk of a chaotic and destructive cellular immune response to the virus. Severe COVID-19 should be considered a virus-induced secondary immune dysregulatory disorder of cellular immunity, with broad host susceptibility. This perspective of COVID-19 will lead to better diagnostic tests, vaccines, and therapeutic strategies in the future.

摘要

简介

COVID-19 对全球社会造成了灾难性的影响。除了至少 600 万人死亡外,数亿人感染了 COVID-19,更多的人陷入了贫困。疫苗已经被证明是有效的,但资金和物流方面的挑战阻碍了它们在全球范围内的快速部署。疫苗分配不均导致了新的 SARS-CoV-2 变体(包括 delta 和 omicron)的出现,使大流行持续存在。

涵盖领域

现在人们对 SARS-CoV-2 的免疫反应有了更好的了解。许多严重疾病的临床表现是由病毒引发的免疫失调引起的。这也许可以解释为什么在疾病后期使用抗病毒治疗(如恢复期血浆输注)效果不佳。

专家意见

T 细胞在 COVID-19 的结果以及对疫苗的保护反应中都起着至关重要的作用。疫苗不能预防感染,但可以降低对病毒产生混乱和破坏性细胞免疫反应的风险。严重的 COVID-19 应被视为一种由病毒引起的继发性免疫调节障碍性细胞免疫紊乱,具有广泛的宿主易感性。这种对 COVID-19 的看法将导致未来更好的诊断测试、疫苗和治疗策略。

相似文献

1
Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.严重的 COVID-19 是由 SARS-CoV-2 引发的 T 细胞免疫失调疾病。
Expert Rev Clin Immunol. 2022 Jun;18(6):557-565. doi: 10.1080/1744666X.2022.2074403. Epub 2022 May 26.
2
The (apparent) antibody paradox in COVID-19.新冠病毒抗体悖论(明显的)。
Expert Rev Clin Immunol. 2022 Apr;18(4):335-345. doi: 10.1080/1744666X.2022.2044797. Epub 2022 Mar 10.
3
SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy.SARS-CoV-2 即亚洲病毒(佐剂诱导的自身免疫/炎症综合征),存在不孕和疫苗犹豫的风险。
Expert Rev Vaccines. 2022 Sep;21(9):1177-1184. doi: 10.1080/14760584.2022.2089120. Epub 2022 Jul 1.
4
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants.一种多表位 SARS-CoV-2 疫苗可提供针对 Delta 和奥密克戎变异株的持久 B 细胞和 T 细胞免疫。
J Clin Invest. 2022 May 16;132(10). doi: 10.1172/JCI157707.
5
SARS-CoV-2 Omicron variant: recent progress and future perspectives.SARS-CoV-2 奥密克戎变异株:最新进展与未来展望。
Signal Transduct Target Ther. 2022 Apr 28;7(1):141. doi: 10.1038/s41392-022-00997-x.
6
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体(RES-Q-HR):一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
7
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染:使用 casirivimab 和 imdevimab(REGN-COV2)单克隆抗体联合治疗后成功清除。
Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.
8
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.恢复期和接种疫苗血清对 SARS-CoV-2 原始株、Beta、Delta 和奥密克戎变异株临床分离株的免疫原性。
Med. 2022 Jun 10;3(6):422-432.e3. doi: 10.1016/j.medj.2022.04.002. Epub 2022 Apr 14.
9
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
10
Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19.常见变异性免疫缺陷病、T 细胞对 SARS-CoV-2 疫苗的反应与慢性 COVID-19 的风险。
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3575-3583. doi: 10.1016/j.jaip.2021.06.019. Epub 2021 Jun 25.

引用本文的文献

1
Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.异体、现成的、针对 SARS-CoV-2 的 T 细胞(ALVR109)治疗高危患者的 COVID-19。
Haematologica. 2023 Jul 1;108(7):1840-1850. doi: 10.3324/haematol.2022.281946.
2
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients.验证T淋巴细胞亚群指数(TLSI)作为预测未接种疫苗的住院COVID-19患者死亡率的评分指标
Biomedicines. 2022 Nov 2;10(11):2788. doi: 10.3390/biomedicines10112788.
3
Induction of pulmonary HLA-G expression by SARS-CoV-2 infection.
新冠病毒感染诱导肺组织 HLA-G 的表达。
Cell Mol Life Sci. 2022 Nov 5;79(11):582. doi: 10.1007/s00018-022-04592-9.
4
Selective IgA Deficiency May Be an Underrecognized Risk Factor for Severe COVID-19.选择性 IgA 缺乏可能是严重 COVID-19 的一个未被充分认识的危险因素。
J Allergy Clin Immunol Pract. 2023 Jan;11(1):181-186. doi: 10.1016/j.jaip.2022.10.002. Epub 2022 Oct 12.
5
SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?SARS-CoV-2 奥密克戎变异株:免疫缺陷患者漫长大流行隧道尽头的曙光,还是又一个虚幻的黎明?
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2267-2273. doi: 10.1016/j.jaip.2022.06.011. Epub 2022 Jun 22.